Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 20/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26617927 | 1.00 | SCN10A (0.66) | SCN10ANR1I2CACNA1C | |
| SCHEMBL30681837 | 1.00 | SCN10A (0.66) | SCN10ANR1I2CACNA1C | |
| SCHEMBL26617446 | 1.00 | SCN10A (0.66) | SCN10ANR1I2CACNA1C | |
| SCHEMBL30682000 | 1.00 | SCN10A (0.66) | SCN10ANR1I2CACNA1C | |
| SCHEMBL24517434 | 0.99 | SCN10A (0.67) | SCN10ANR1I2CACNA1C | |
| SCHEMBL24517742 | 0.97 | SCN10A (0.67) | SCN10ANR1I2CACNA1C | |
| SCHEMBL26617579 | 0.91 | SCN10A (0.65) | SCN10ANR1I2CACNA1C | |
| SCHEMBL26617676 | 0.91 | SCN10A (0.56) | SCN10ANR1I2CACNA1C | |
| SCHEMBL26617562 | 0.90 | SCN10A (0.55) | SCN10ANR1I2CACNA1C | |
| SCHEMBL30681941 | 0.90 | SCN10A (0.63) | SCN10ANR1I2CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514789-A1 | <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN | SiteOne Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |